Condition (MeSH)
Central Nervous System Vascular Malformations
ClinicalTrials.gov lists 73 trials for Central Nervous System Vascular Malformations or a narrower condition beneath it. Microvention-Terumo, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
11 of the 73 trials are tagged with Central Nervous System Vascular Malformations itself; the rest are tagged with a narrower condition beneath it.
When did Central Nervous System Vascular Malformations trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 11
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 7 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 5 |
| 2018 | 11 |
| 2017 | 5 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 38 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Central Nervous System Vascular Malformations trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Not applicable | 20 |
| Observational | 40 |
How many Central Nervous System Vascular Malformations trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 14 |
| Active, not recruiting | 3 |
| Completed | 29 |
| Terminated | 6 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Central Nervous System Vascular Malformations trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Microvention-Terumo, Inc. | 3 |
| Fondation Ophtalmologique Adolphe de Rothschild | 2 |
| Balt Extrusion | 1 |
| Basecamp Vascular | 1 |
Which drugs are being tested for Central Nervous System Vascular Malformations? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Lovastatin | 1 |
| ATORVASTATIN | 1 |
| SIMVASTATIN | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Propranolol PO | 2 |
| REC-994 | 1 |
| Biocollection | 1 |
| Observational | 1 |
| Single in situ intra-arterial injection of bevacizumab | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Central Nervous System Vascular Malformations trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute kidney injury | 1 | 1 |
| Acute myocardial infarction | 1 | 1 |
| Aortic dissection | 1 | 1 |
| Complete chorion-amnion separation | 1 | 1 |
| Elevated creatine kinase (CK) | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Central Nervous System Vascular Malformations? (42)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Dural arteriovenous fistula research and management in China (DREAM-INI): initial characterization and patient cohort outcomes. | Journal of neurointerventional surgery | 2026 | Yes |
| Tentorial Dural Arteriovenous Fistulas: A Retrospective Cohort Study. | Operative neurosurgery (Hagerstown, Md.) | 2025 | Yes |
| A phase II double-blind multicentre, placebo-controlled trial to assess the efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM study protocol. | BMJ open | 2024 | Yes |
| Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation. | Journal of the American Heart Association | 2023 | Yes |
| Endovascular Treatment of Cavernous Sinus Dural Arteriovenous Fistulas. Institutional Series, Systematic Review and Meta-Analysis. | Clinical neuroradiology | 2022 | Yes |
Showing 5 of 42 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.